Marqueurs tumoraux et tumeurs germinales du testicule

  • D. Bellet
  • F. Troalen
Part of the Monographies en urologie book series (MONOGRAPHIES)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bosl GJ, Motzer J (1997) Testicular germ-cell cancer. New Eng J Med 337: 242–53PubMedGoogle Scholar
  2. 2.
    International Germ Cell Cancer Collaboration Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594–603Google Scholar
  3. 3.
    Horwich A, Huddart R, Dearnaley D (1998) Markers and management of germ-cell tumours of the testes. Lancet 352: 1535–8PubMedCrossRefGoogle Scholar
  4. 4.
    Eschwege P, Benoit G (2002) Tumeurs du testicule. Rev Prat 52: 1119–24PubMedGoogle Scholar
  5. 5.
    Korhonen J, Afthan H, Ylostalo P et al. (1997) Disappearance of human chorionic gonadotropin and its α and β-subunits after term pregnancy. Clin Chem 43: 2155–63PubMedGoogle Scholar
  6. 6.
    Bidart JM, Bellet D (1993) Human Chorionic Gonadotropin: Molecular forms, detection and clinical implications. Trends Endocrinol Metab 4: 285–91PubMedGoogle Scholar
  7. 7.
    Bellet D, Lazar V, Bieche I et al. (1997) Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin beta genes normally transcribed in trophoblastic cells. Cancer Res 57: 516–23PubMedGoogle Scholar
  8. 8.
    Berger P, Sturgeon C, Bidart JM et al. (2002) The ISOBM TD-7 workshop on hCG and related molecules. Tumor Biol 23: 1–38CrossRefGoogle Scholar
  9. 9.
    Ozturk M, Bellet D, Manil L et al. (1987) Physiological studies of human chorionic gonadotropin (hCG), αhCG, and βhCG as measured by specific monoclonal immunoradiometric assays. Endocrinology 120: 549–55PubMedGoogle Scholar
  10. 10.
    Bellet D, Ozturk M, Bidart JM et al. (1986) Sensitive and specific assay for human chorionic gonadotropin (hCG) based on anti-peptide and anti-hCG monoclonal antibodies: construction and clinical implications. J Clin Endocrinol Metab 63: 1319–27PubMedCrossRefGoogle Scholar
  11. 11.
    Afthan H, Haglund C, Dabek J et al. (1992) Concentrations of human choriogonadotropin, its β-subunit and the core fragment of the β-subunit in serum and urine of men and nonpregnant women. Clin Chem 38: 1981–7Google Scholar
  12. 12.
    Keller RH, Lyman S (1982) α-foetoprotein: biological and clinical potential. In: Rhodes BA, ed. Tumor imaging. New York: Masson Publishing: 41–52Google Scholar
  13. 13.
    Kamoto T, Satomura S, Yoshiki T et al. (2002) Lectin-reactive alpha-foetoprotein (AFPL3 %) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn J Clin Oncol 32: 472–6PubMedCrossRefGoogle Scholar
  14. 14.
    Bellet D, Wands JR, Isselbacher KJ et al. (1984) Serum α-foetoprotein levels in human disease: perspective from a highly specific monoclonal radioimmunoassay. Proc Natl Acad Sci USA 8: 3869–73Google Scholar
  15. 15.
    Liu F, Fritscher HA, Trujillo JM et al. (1982) Serum lactate deshydrogenase isoenzyme 1 in patients with advanced testicular cancer. Am J Clin Path 78: 178–82PubMedGoogle Scholar
  16. 16.
    Schmoll HJ, Beyer J, Pro J (1998) Prognostic factors in metastatic germ cell tumors. Semin Oncol 25: 174–86PubMedGoogle Scholar
  17. 17.
    Koshida K, Nishino A, Yamamoto H et al. (1991) The role of alkaline phosphatase isoenzymes as tumor markers for testicular germ cell tumors. J Urol 146: 47–60Google Scholar
  18. 18.
    Tandstad T, Klepp O (2003) Neuron-specific enolase in testicular cancer. Acta Oncol 42: 202–6PubMedCrossRefGoogle Scholar
  19. 19.
    Treatment of testicular cancer (1985) Lancet: 258–9Google Scholar
  20. 20.
    Oliver RTD (1985) Factors contributing to delay in diagnosis of testicular tumours. Br Med J 290: 356CrossRefGoogle Scholar
  21. 21.
    Steele JPC, Oliver RTD (2002) Testicular cancer: perils of very late presentation. Lancet 359: 1632–3PubMedCrossRefGoogle Scholar
  22. 22.
    Bellet D, Ranke A, Bressac B et al. (1989) Intérêt de l’alpha-foetoprotéine, de l’hormone chorionique gonadotrope et de sa sous-unité bêta libre pour le diagnostic, le pronostic et la surveillance des tumeurs germinales du testicule. In: Les marqueurs tumoraux, M Bolla et P Martin (Eds), Masson: 81–8Google Scholar
  23. 23.
    Hoshi S, Suzuki K, Ishidoya S et al. (2000) Significance of simultaneous determination of serum human chorionic gonadotropin (hCG) and hCG-beta in testicular tumor patients. Int J Urol 7: 218–23PubMedCrossRefGoogle Scholar
  24. 24.
    Mencel PJ, Motzer RJ, Mazumdar M et al. (1994) Advanced seminoma: treatment, results, survival, and prognosis factors in 142 patients. J Clin Oncol 12: 120–6PubMedGoogle Scholar
  25. 25.
    Canil CM, Tannock IF (2002) Doctor’s dilemma: incorporating tumor markers into clinical decision-making. Semin Oncol 29: 286–93PubMedCrossRefGoogle Scholar
  26. 26.
    Mazumdar M, Bajorin DF, Bacik J et al. (2001) Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotropin and alpha-foetoprotein during therapy. J Clin Oncol 19: 2534–41PubMedGoogle Scholar
  27. 27.
    Toner GC, Geller CK, Tan C et al. (1990) Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in non seminomatous germ cell tumors. Cancer Res 50: 5904–10PubMedGoogle Scholar
  28. 28.
    Gerl A, Lamerz R, Clemm C et al. (1996) Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin Cancer Res 2: 1565–70PubMedGoogle Scholar
  29. 29.
    Picozzi VJ, Freiha FS, Hannigan JF et al. (1984) Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germcell carcinoma. Ann Intern Med 100: 183–6PubMedGoogle Scholar
  30. 30.
    Horwich A, Peckham MJ (1986) Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. Cancer Treat Rep 70: 1329–31PubMedGoogle Scholar
  31. 31.
    Vogelzang NJ, Lange PH, Goldman A et al. (1982) Acute changes of α-foetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 42: 4855–61PubMedGoogle Scholar
  32. 32.
    Horwich A, Peckham MJ (1984) Serum tumour marker regression rate following chemotherapy for malignant teratoma. Eur J Cancer Clin Oncol 20: 1463–70PubMedCrossRefGoogle Scholar
  33. 33.
    Droz JP, Kramar A, Nichols CR et al. (1995) Second line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in recurrent germ cell cancer: Assignment of prognosis groups. Proc Am Soc Clin Oncol 12: 229 (abstr 704)Google Scholar
  34. 34.
    Murphy BA, Motzer RJ, Mazumdar M et al. (1994) Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 73: 2520–6PubMedGoogle Scholar
  35. 35.
    Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48: 1151–9PubMedGoogle Scholar
  36. 36.
    Morris MJ, Bosl GJ (2000) Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urol 163: 796–801PubMedGoogle Scholar
  37. 37.
    Coppacks S, Newlands ES, Dent J et al. (1983) Problems of interpretation of serum concentrations of alpha-foetoprotein (AFP) in patients receiving cytotoxic chemotherapy for malignant germ cell tumours. Br J Cancer 48: 335–40Google Scholar
  38. 38.
    Grem JL, Trump DL (1986) Reversible increase in serum α-foetoprotein content associated with hepatic dysfunction during chemotherapy for seminoma. J Clin Oncol 4: 41–5PubMedGoogle Scholar
  39. 39.
    Pandha HS, Wasan HS, Harrington K et al. (1995) Lesson of the week: failure of normalisation of (alpha) foetoprotein concentration after successful treatment of teratoma. BMJ 311: 434–5PubMedGoogle Scholar
  40. 40.
    Flechon A, Droz JP (2001) Hereditary persistence of α-foetoprotein in testis disease. J Urol 165: 2004PubMedGoogle Scholar
  41. 41.
    Braunstein GD (2002) False-positive serum human chorionic gonadotropin results: causes, characteristics, and recognition. Am J Obstet Gynecol 187: 217–24PubMedCrossRefGoogle Scholar
  42. 42.
    Mills JN, Nguyen TT, Williams RD (2001) Falsely increased β-human chorionic gonadotropin with a testicular epidermoid cyst. 166: 2314Google Scholar
  43. 43.
    Bulger KN, Hesketh PJ, Babayan RK (1989) Discordant human chorionic gonadotropin results giving rise to inappropriate therapy in a case of testicular cancer. J Urol 142: 1574–5PubMedGoogle Scholar
  44. 44.
    Kricka LJ (1999) Human anti-animal antibody interferences in immunological assays. Clin Chem 45: 942–56PubMedGoogle Scholar
  45. 45.
    Mazumdar M, Bacik J, Tickoo SK et al. (2003) Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-foetoprotein, and human chorionic gonadotropin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor. J Clin Oncol 21: 2679–88PubMedCrossRefGoogle Scholar
  46. 46.
    Brachmann AA, Beyer J, Jager R et al. (2003) Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol 14: 1525–9PubMedGoogle Scholar
  47. 47.
    Aubry F, Satie AP, Rioux-Leclercq N et al. (2001) MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer 92: 2778–85PubMedGoogle Scholar
  48. 48.
    Hechelhammer L, Storkel S, Odermatt B et al. (2003) Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors. Virchows Arch 443: 28–31PubMedCrossRefGoogle Scholar
  49. 49.
    Mandoky L, Geczi L, Bodrogi I et al. (2003) Expression of HER-2/neu in testicular tumors. Anticancer Res 23: 3447–51PubMedGoogle Scholar
  50. 50.
    Huyghe E, Matsuda T, Thonneau P (2003) Increasing incidence of testicular cancer worldwide: a review. J Urol 170: 5–11PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2006

Authors and Affiliations

  • D. Bellet
    • 1
  • F. Troalen
    • 2
  1. 1.Service de biologie du Pr BelletInstitut Gustave-RoussyVillejuif Cedex
  2. 2.Institut Gustave RoussyVillejuif Cedex

Personalised recommendations